0 projects

Date from new to old

GLOBHELS-Global helse

Development of biodegradable nanobeads as vaccines against tuberculosis.

Tuberculosis (TB), which is caused by infection with the bacterium Mycobacterium tuberculosis (M.tb), is a major burden globally and causes more than 1,3 million deaths every year. The only available vaccine against TB, the live vaccine Bacille Calmette Guerin (BCG), is however largely ineffectiv...

Awarded: NOK 3.7 mill.

Project Period: 2012-2017

Location: Oslo

GLOBHELS-Global helse

Conference: Incorporating Equity and Non-Health Outcomes in Health Priorities

...

Awarded: NOK 0.12 mill.

Project Period: 2011-2012

Location: Vestland

GLOBHELS-Global helse

Vaccine development in Orientia tsutsugamushi infection

Awarded: NOK 3.7 mill.

Project Period: 2010-2014

Location: Oslo

GLOBHELS-Global helse

Advancing Rotavirus Vaccine Development (ARVAC) - BBIL Phase 3 Study

PATH?s Advancing Rotavirus Vaccine Development (ARVAC) project, the Indian Department of Biotechnology (DBT), and Bharat Biotech International, Ltd. (BBIL) conducted a Phase 3 efficacy study of BBILs 116E (ROTAVAC®) rotavirus vaccine, and an Expanded Program on Immunization (EPI) non?interference...

Awarded: NOK 23.3 mill.

Project Period: 2010-2017

Location: Ukjent Fylke

GLOBHELS-Global helse

'Communicate to vaccinate': Building evidence for improving communication about childhood vaccinations in low- and middle-income countries

Background Effective provider-parent communication can improve childhood vaccination uptake and strengthen immunization services in low- and middle-income countries (LMICs). Building capacity to improve communication strategies has been neglected. Rigorou s research exists but is not readily foun...

Awarded: NOK 4.0 mill.

Project Period: 2010-2013

Location: Oslo

GLOBHELS-Global helse

Vaccibodies for SIV: a step towards an HIV vaccine for humans.

Aim: Vaccibodies are recombinant vaccine molecules that can target antigen presenting cells (APC) and enhance immune responses towards the delivered antigen. The primary objective of the present proposal is to develop Vaccibodies for simian immunodeficien cy virus (SIV) and to test whether they e...

Awarded: NOK 3.1 mill.

Project Period: 2010-2013

Location: Oslo

GLOBHELS-Global helse

Novel vaccine candidates against meningococcal disease

Meningococcal disease is a leading cause of meningitis and septicaemia globally, most often striking small children and teenagers. Due to the lack of efficient vaccines, serogroup B meningococcal disease is currently emerging on a worldwide basis. The rat ional design of outer membrane protein-ba...

Awarded: NOK 4.0 mill.

Project Period: 2010-2013

Location: Oslo

GLOBHELS-Global helse

Molecular control of T cell memory

Awarded: NOK 5.5 mill.

Project Period: 2010-2014

Location: Oslo

GLOBHELS-Global helse

Health systems strengthening within vaccination programmes: an ethnographic study (HEALVAC)

Within the global health field, donors, policymakers and researchers often emphasise the importance of “health system strengthening”. Health system strengthening has become a buzzword, but there is actually a great deal of ambiguity about what it means – to different people, at different levels o...

Awarded: NOK 3.6 mill.

Project Period: 2010-2016

Location: Oslo

GLOBHELS-Global helse

Phase III rotavirus vaccine trials in India: Bilateral competence building

Each year, approximately 2 million children worldwide die from diarrhea, one fourth of these are caused by rotavirus infections. Indian scientists have developed a live, oral Rotavirus Vaccine (HRV 116E) which is being evaluated in a phase III trial partl y funded by the Research council of Norwa...

Awarded: NOK 6.4 mill.

Project Period: 2010-2014

Location: Oslo

GLOBHELS-Global helse

IgA antibodies in saliva as a noninvasive readout for intestinal immune responses

Enterotoksigene Escherichia coli (ETEC) utgjør en vesentlig årsak til diare hos barn i land med lav og middel s inntekt. ETEC bindes til epitelet i tarmen ved hjelp av koloniseringsfaktorer og forårsaker diare ved å frigi enteretoksiner. Det er behov for et ikke-invasivt korrelat som mål for bes...

Awarded: NOK 0.81 mill.

Project Period: 2010-2016

Location: Oslo

GLOBHELS-Global helse

Additional activities related to an ongoing project: Impact of the new vaccine MenAfriVac on carriage of serogroup A Neisseria meningitidis

Meningitis due to Neisseria meningitidis serogroup A represents an important public health problem in sub-Saharan Africa. New meningitis vaccines (against pneumococci, Hemophilus influenzae and serogroup C meningococci) manufactured by conjugating the pol ysaccharide to a carrier protein have bee...

Awarded: NOK 2.9 mill.

Project Period: 2010-2012

Location: Oslo

GLOBHELS-Global helse

Development of a food-grade Lactobacillus-based oral vaccine delivery system

In low-income countries, efforts to increase immunization coverage are hampered by weak health systems. Furthermore, the unaffordable costs of some vaccines remain a major barrier for people to access vaccination services. To develop novel technologies fo r effective production and delivery of va...

Awarded: NOK 3.1 mill.

Project Period: 2010-2013

Location: Akershus

GLOBHELS-Global helse

mVAC - Mobile innovations in recording child vaccination and health data in immunization registers

We will develop an innovative and mobile phone based solutions to create a fully digital system for recording immunizations at the individual level, which can be implemented in countries both with and without a public unique person ID structure/system. Pr imary health care workers will be equippe...

Awarded: NOK 5.4 mill.

Project Period: 2010-2014

Location: Vestland

GLOBHELS-Global helse

Studies of humoral and cell-mediated protective immune markers during Mycobacterium tuberculosis infection in human population

Prosjektet har resultert i betydelige resultater i form av publikasjoner og presentasjoner på konferanser siden vår siste rapport i juli, 2014. Vi har nå gjennomført analyse og er ferdige med resultatet. Artikkelen "QuantiFERON-TB gold in-tube-test Conversions and reversions among tuberculosis pa...

Awarded: NOK 3.8 mill.

Project Period: 2010-2015

Location: Oslo

GLOBHELS-Global helse

To what extent do user fees affect Hepatitis B vaccine coverage rates in China?

China has 93 million infected carriers of the HB virus; about 20 million with chronic infections. The main transmission of virus is vertical, within families, often from mother to child during childbirth. The probability for developing chronic infection i s 90% for infants (infected in first year...

Awarded: NOK 3.9 mill.

Project Period: 2010-2013

Location: Oslo

GLOBHELS-Global helse

Biomarkers of mycobacterial infection and disease, and molecular characterization of mycobacteria from high TB-burden countries.

Tuberculosis (TB) is a major public health problem throughout the world. Currently, there are 8 million new cases and 2-3 million deaths annually from TB. More than 95% of all cases and 98% of all deaths occur in developing countries, where few resources are available to ensure proper treatment....

Awarded: NOK 3.0 mill.

Project Period: 2010-2013

Location: Vestland

GLOBHELS-Global helse

Target cell recognition by natural killer cells

NK-celler utgjør omlag 5% av hvite blodlegemer. I tillegg til å drepe kreftceller kan NK-celler oppdage og drepe celler som er infisert med intracellulære mikroorganismer, slik som virus og visse typer bakterier og parasitter. Intracellulære infeksjoner kan være vanskelige å forebygge ved vaksi...

Awarded: NOK 3.9 mill.

Project Period: 2010-2016

Location: Oslo

GLOBHELS-Global helse

Expression and evaluation of envelope domain III-based experimental tetravalent dengue vaccine using tobacco chloroplast expression system

Results from the whole project period (Oct 2009-June 2014) Background: Dengue viruses are mosquito-borne human pathogens with a worldwide prevalence. There are four different dengue virus serotypes, DEN-1 to DEN-4, which cause serious problems of morbidity and mortality. Dengue is emerging ra...

Awarded: NOK 9.9 mill.

Project Period: 2009-2015

Location: Akershus

GLOBHELS-Global helse

Preparing for tuberculosis vaccine efficacy trials: Identifying at-risk individuals for TB vaccine trials.

Tuberkulose (TB) utgjør en betydelig trussel mot folkehelsen på verdensbasis. Forskningsnettverket «TB Trials», som består av forskere i Danmark, India, Norge, Sør-Afrika og USA, har gjennomført tre store prospektive observasjonelle kohortestudier i Palamaner i sørlige India for å bidra med vikti...

Awarded: NOK 4.6 mill.

Project Period: 2009-2016

Location: Vestland

GLOBHELS-Global helse

Mucosal vaccination against autoimmune disease

Tolerance-induction via mucosal routes is a well recognized method to protect against autoimmune disease in experimental animal models. Unfortunately, as successful protocols from e.g murine models have been taken into clinical trials the results have bee n poor, even though very large doses of p...

Awarded: NOK 7.9 mill.

Project Period: 2009-2013

Location: Vestland

GLOBHELS-Global helse

Development of novel vaccine candidates to prevent primary or reactivated tuberculosis

Mycobacterium tuberculosis is among the major infectious pathogens in the world, and has a considerable impact on children and adults of disease endemic countries. Increasing spread of multi-drug-resistant tuberculosis and the general failure of the BCG v accine, have made vaccine development aga...

Awarded: NOK 4.0 mill.

Project Period: 2009-2013

Location: Vestland

GLOBHELS-Global helse

Application of Open Source Licensing to Vaccine and Medicine Discovery and Development

This proposal will focus on the application of open source licensing to vaccine and drug discovery and development. Open source licensing, widely used within the computer software industry, allows an individual to share intellectual property rather than c opyrighting or patenting it. The main g...

Awarded: NOK 2.7 mill.

Project Period: 2009-2013

Location: Oslo

GLOBHELS-Global helse

Integration and scaling of health information system to strengthen vaccination services delivery in india

Improving effectiveness, coverage, equity and affordability of immunization programs is central to the Indian NRHM agenda, with the key strategy being to strengthen information support for program monitoring and evaluation. Core to this is an integrated a nd decentralised Health Information Syste...

Awarded: NOK 3.0 mill.

Project Period: 2009-2013

Location: Oslo

GLOBHELS-Global helse

Development of a proposal on Norwegian engagement and collaborative projects in a phase III trial of oral rotavirus vaccine ORV 116E in Indi

See project descrioption

Awarded: NOK 0.50 mill.

Project Period: 2009-2010

Location: Oslo

GLOBHELS-Global helse

Improved vaccination responses and optional immunomodulating therapy by adjuvant administration of COX-2 inhibitor in HIV-infected patients

This Proposal results from translational HIV research by the Applicants, ranging from basic research on signal transduction in lymphocytes that has firmly established cyclic AMP (cAMP) / protein kinase A type I alpha as a major inhibitor of antigen-specif ic activation; to basic clinical studies ...

Awarded: NOK 4.2 mill.

Project Period: 2009-2015

Location: Oslo

GLOBHELS-Global helse

A rapid serological screening method for detecting tuberculosis disease and monitoring the efficacy of new vaccines

The development of new diagnostic tools and more effective vaccines are essential to combat the global tuberculosis (TB) pandemic. The lack of a widely accessible screening test that is easy to perform without laboratory facilities is one of the main reas ons for the unacceptable delay in diagnos...

Awarded: NOK 12.8 mill.

Project Period: 2009-2013

Location: Oslo

GLOBHELS-Global helse

Studies to complete the phase II clinical stage of development for the peptide-based HIV-1 therapeutic vaccine candidate Vacc-4x.

Combination antiretroviral therapy (ART) for HIV infection has improved the longevity of infected individuals and as new infections occur each year, the overall number in need of ART is rising increasing the financial burden for healthcare services. ART l imitations include increasing multidrug r...

Awarded: NOK 7.5 mill.

Project Period: 2009-2012

Location: Oslo

GLOBHELS-Global helse

Development of an outer membrane vesicle vaccine for Africa against serogroup A and W-135 meningococcal disease

Epidemics of meningococcal disease are a significant health problem in most African countries, and there is a strong need for improved and affordable vaccines. We are here proposing a collaborative program between Norway, Cuba and Ethiopia to provide a ne w approach for prevention of bacterial me...

Awarded: NOK 6.7 mill.

Project Period: 2009-2014

Location: Oslo

GLOBHELS-Global helse

Developing vaccines against diarrhea caused by Enterotoxigenic Escherichia coli and Shigella (EntVac)

Diarrhea and dysentery are important killers of children in developing countries. These diseases also contribute to malnutrition. Vaccines give a very favorable return on public health investment, and a polyvalent anti-diarrheal vaccine would greatly impr ove this investment case. But efforts to ...

Awarded: NOK 15.2 mill.

Project Period: 2008-2014

Location: Vestland

1 2 3